medigraphic.com
ISSN 1561-2945 (Print)

2020, Number 1

<< Back Next >>

Revista Cubana de Cirugía 2020; 59 (1)

A Gigantic Gastrointestinal Stroma Tumor of the Stomach

González GJL

Language: Spanish
References: 28
Page: 1-10
PDF size: 297.41 Kb.


ABSTRACT

Gastrointestinal stromal tumors are the most frequent mesenchymal tumors of the gastrointestinal tract, and are malignant in 20-45 %. They originate from Cajal cells or their precursors. The most frequent clinical symptoms are the presence of an abdominal tumor, digestive hemorrhage due to mucosa ulceration, and pain or sensation of abdominal fullness. These tumors may have a long period of silent growth until, due to their size, they manifest clinically; they tend to have expansive growth, displacing neighboring structures without invading them. We present the case of a patient with a gastrointestinal stroma tumor of the stomach of unusually large proportions, who underwent surgery by our team and with a satisfactory evolution.


REFERENCES

  1. Stout AP. Bizarre smooth muscle tumors of the stomach. Cancer. 1962;15:400-09.

  2. Mazur MT, Clark HB. Gastric stromal tumors: Reappraisal of histogénesis. Am J Surg Pathol. 1983;7:507-19.

  3. Schaldenbrand JD, Appelman HD. Solitary solid stromal gastrointestinal tumors in von Recklinghausen´s disease with minimal smooth muscle differentiation. Hum Pathol. 1984;15:229-32.

  4. Herrera GA, Cerezo L, Jones JE. Malingnant small bowel neoplasm of enteric plexos derivation (plexosarcoma). Light and electron microscopio stady confirming the origin of the neoplasm. Dig Dis SCI. 1984;29:275-84.

  5. Lee YTM: Leiomyosarcoma of the gastro-intestinal tract: general patern of metástasis and recurrence. Cancer Treat Rev. 1983;10:91-101.

  6. Lauwers GY, Erlanson RA, Casper ES. Gastrointestinal autonomic nerve tumors: A clinicopathologic, inmunohistochemical and ultraestructural study of 12 cases. Am J Surg Pathol. 1993;17:887-97.

  7. Pidhorecky I, Cheney R. Gastrointestinal Stromal Tumors: Current Diagnosis, Biologic Behavior, and Management. Annals of Surgical Oncology. 2000;7(9):705-12.

  8. Dougherty MJ, Compton C, Talbert M. Sarcomas of the Gastrointestinal tract. Ann Surg 1991;214:569-74.

  9. Langer C, Gunawan B. Prognostic factors influencing surgical management and outcome of gastrointestinal stromal tumours. British Journal of Surgery. 2003;90:332-9.

  10. Ueyama T, Guo KJ, Hashimoto H. A clinicopathologic and inmunohistochemical study of gastrointestinal stromal tumors. Cancer. 1992;69:947-55.

  11. Appelman HD, Helwig EB. Cellular leiomyomas of the stomach in 49 patients. Arch Pathol Lab Med. 1977;101:373-7.

  12. Appelman HD, Helwiq EB. Sarcomas of the stomach. Am J Clin Pathol. 1977;67:2-10.

  13. Emory TS, Sobón LH, Lukes L, Lee DH. Prognonosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Pathol. 1999;23:82-7.

  14. Kindblom LG, Remotti HE. Gastrointestinal Pacemaker Cell Tumor (GIPACT): Am J Pathol. 1998;152(5):1259-69.

  15. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.

  16. Goldblum JR, Appelman HD. Stromal tumors of the duodenum: A histologic and immunohistochemical study of 20 cases. Am J Surg Pathol. 1995;19:71-80.

  17. Brainard JA, Goldblum JR. Stromal tumors of jejunum and ileum: A clinicopathologic study of 39 cases. Am J Surg Pathol. 1997;21:407-16.

  18. Lehnert T. Gastrointestinal Sarcoma (GIST)- A review of Surgical Management. Annales Chirurgiae et Gynaecologiae. 1998;87:297-305.

  19. Santiago Frioni P Tumores Estromales del Tubo digestivo Hospital Maciel Montevideo Uruguay. Monografía. 2005;1:269.

  20. Dematteo RP, Ballman KV, Antonescu CR. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. 2009:373(9669):1097-1104.

  21. Fletcher CD, Berman JJ, Corless C. Diagnosis of gastro intestinal stromal tumors: A consensus approach. Human pathology. 2002;33(5):459-65.

  22. Hameed M, Corless C, George S. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Gastrointestinal Stromal Tumors. Arch Pathol Lab Med. 2015;139(10):1271-5.

  23. Kattan MW, Hess KR. Amin MB. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. Cáncer journal for clinicians; 2016.

  24. Joen H, Rutkowski P, Nishida T. KIT and PDGFRA mutations and the risk o f GI stromal tumo r recurrence. J Clin Oncol. 2015;33(6):634-42.

  25. Corless CL, Ballman KV, Antonescu CR. Pathologic and molecular features correlate with long-term outeome after adjuvant therapy of resected primary Gl stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32(15):1563-1570.

  26. Joensu H, Eriksson M, Sundby Hall K. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a rand omized trial. JAMA. 2012:307(12):1265-72.

  27. American Joint Committee on Cancer. Springer International Publishing. 2017;3-319-40617-6. ISBN 978.

  28. Demetri GD, Reichardt P, Kang YK. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295-302.




2020     |     www.medigraphic.com